Adcetris
(Brentuximab vedotin)ApprovedAntibody–drug conjugate
PfizerBrentuximab vedotin is used to treat certain types of lymphomas (blood cancers) and a skin cancer called cutaneous T-cell lymphoma. It works by targeting cancer cells and delivering chemotherapy directly to them.[2] Adcetris is currently approved and in use across 20 indications[4].[1]
Adcetris is one of 247 small molecule programs targeting Classic Hodgkin Lymphoma. It is currently in Approved.
20
Indications
165
Total Trials
49
Active Trials
246
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 20 indications
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Adcetris
PfizerApproved
Norvir
AbbViePreclinical
Cabenuva
GSKPreclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2026
Phase 2Recruiting
Lymphoma
NCT04561206
Phase 3Active, not recruiting
Ann Arbor Stage IIB Hodgkin Lymphoma
NCT02166463
Phase 2Active, not recruiting
Advanced Hodgkin Lymphoma
NCT03517137
Phase 2Recruiting
Lymphoma
NCT05180097
PreclinicalActive, not recruiting
Recurrent Classic Hodgkin Lymphoma
NCT01896999
Phase 3Active, not recruiting
Diffuse Large B-Cell Lymphoma
NCT04404283
Clinical
Trials by Indication[1]
Lymphoma82 trials
Show 79 more trials
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
Withdrawn·—·Phase 1·NCT03373305
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
Active, not recruiting·—·Phase 2·NCT02758717·46 enrolled
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Completed·—·Phase 1·NCT03013933·29 enrolled
Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
Completed·—·Phase 1/2·NCT01994850·32 enrolled
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 1/2·NCT02243436·67 enrolled
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Recruiting·—·Phase 2·NCT04561206·31 enrolled
OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy
Unknown status·KKing Abdullah International Medical Research Center·Phase 2·NCT03527628·220 enrolled
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT01900496·6 enrolled
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Completed·—·Phase 2·NCT02744612·39 enrolled
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Unknown status·—·Phase 2·NCT06201507·44 enrolled
BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas
Enrolling by invitation·NN.N. Petrov National Medical Research Center of Oncology·Phase 3·NCT07258680·114 enrolled
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
Active, not recruiting·—·Phase 2·NCT03057795·62 enrolled
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
Completed·—·Phase 2·NCT01393717·57 enrolled
Brentuximab Vedotin14 trials
Show 11 more trials
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT05149768·11 enrolled
Anaplastic Large Cell Lymphoma8 trials
Diffuse Large B-Cell Lymphoma7 trials
Show 4 more trials
Mycosis Fungoides5 trials
Show 2 more trials
33 more indications
Hodgkin Lymphoma5 trials
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Active, not recruiting·AAcademic and Community Cancer Research United·Phase 2·NCT03233347·83 enrolled
Show 2 more trials
Cutaneous T-cell lymphoma4 trials
Germ Cell Tumor3 trials
Classic Hodgkin Lymphoma3 trials
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
Active, not recruiting·—·Phase 2·NCT03712202·155 enrolled
Recurrent Classic Hodgkin Lymphoma3 trials
Systemic Sclerosis2 trials
Brentuximab Vedotin for Systemic Sclerosis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03222492·17 enrolled
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT03198689·11 enrolled
Relapsed or Refractory2 trials
Relapsed/Refractory2 trials
Treatment1 trial
Systemic Mastocytosis1 trial
Hematologic Malignancies1 trial
Allogeneic Stem Cell Transplantation1 trial
Allogeneic Hematopoietic Stem Cell Transplantation1 trial
Advanced Hodgkin Lymphoma1 trial
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03517137·150 enrolled
CD30-Positive Neoplastic Cells Present1 trial
NK-Cell Lymphoma1 trial
Peripheral T-Cell Lymphoma1 trial
Recurrent Hodgkin Lymphoma1 trial
Lymphomatoid Papulosis1 trial
Stage III1 trial
Ann Arbor Stage IIB Hodgkin Lymphoma1 trial
Melanoma1 trial
Recurrent Follicular Lymphoma1 trial
Regulatory
FDA Approval Timeline[5]
Aug 19, 2011
ADCETRIS
BLA BLA125388
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Adcetris drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Brentuximab vedotin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]